



Oslo Cancer Cluster invites you to join
Cancer Crosslinks 2022
January 27, 2022

Getting Ahead of Tumor Evolution - Changing the Premises in the War Against Cancer

Join distinguished speakers from the UK, USA, Germany, Switzerland, Canada, and Norway as they discuss recent progress in the understanding of tumor evolution and emerging diagnostic and treatment options for solid and hematological cancers. Cancer Crosslinks will be streamed from Oslo Cancer Cluster Innovation Park. Visit the website to learn about attendance options (daytime meeting and/or afternoon networking event at 16:15 CET).

Daytime

Thursday, January 27, 2022
11:45 – 16:15 (CET) Digital & On-site with Networking

Speakers & Topics

- **Mariam Jamal-Hanjani**, UCL Cancer Institute London, UK
Tracking Lung Cancer Evolution from Early to Late-Stage Disease - Its Clinical and Therapeutic Implications
- **David Rimm**, Yale University School of Medicine, New Haven, USA
Current and Future Methods of Predicting Response to Immunotherapy
- **Martin Schuler**, University Hospital Essen, Germany
Immunotherapy Trials in the Perioperative Setting - Opportunity for Clinical Proof-of-Concept and Mechanistic Exploration
- **Angela George**, Royal Marsden Hospital, London, UK
Precision Therapy for Gynecological Cancers with Focus on Endometrial (Uterine) Cancer – Molecular Subtypes & Emerging Treatment Options
- **Christoph Driessen**, Kantonsspital St. Gallen, St Gallen, Switzerland
Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors (The Proteasome and Proteasome Inhibitors: From Biology to Clinical Impact)
- **Bertrand Routy**, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
Gut Microbiome in the Immunotherapy Arena: From Biomarker to Therapeutics

Afternoon

Starting at 16:15 (CET)
On-Site Networking Event

To register, visit: www.cancercrosslinks.com

For more information about this meeting, please contact:

Jutta Heix, jh@oslocancercluster.no or Charlotte Wu Homme, cwh@oslocancercluster.no

Sponsored by:



Program

14th Cancer Crosslinks 2022

Thursday, January 27, 2022– presented as a Live Produced Digital Meeting / complemented by Roundtables and networking opportunities (tbd based on COVID-19 related restrictions in Jan 2022)

Getting ahead of tumor evolution – changing the premises in the war against cancer	
11:45 – 12:00	Registration on-site & Log-in for live-stream
12:00 - 12:10	Opening and Welcome
	Moderators: Kristina Lindemann , Head of Research, Dept. of Gynecological Oncology, Oslo University Hospital and Åsmund Flobak , St. Olavs Hospital, Trondheim University Hospital
12:10 - 12:50	Tracking lung cancer evolution from early to late-stage disease – its clinical and therapeutic implications Mariam Jamal-Hanjani , Group Leader, Cancer Metastasis Lab, CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute; Senior Clinical Lecturer and Honorary Consultant in Translational Lung Oncology, UCL Hospital, London, UK
12:50 - 13:30	Current and future methods of predicting response to Immunotherapy David Rimm , Anthony N. Brady Professor of Pathology, Professor of Medicine (Oncology), Director, Translational Pathology and Director, Yale Pathology Tissue Services; Director, Physician Scientist Training Program in Pathology, Yale University School of Medicine, New Haven, USA
13:30 - 13:50	COFFEE BREAK
13:50 - 14:20	Immunotherapy trials in the perioperative setting – Opportunity for clinical proof-of-concept and mechanistic exploration Martin Schuler , Professor, Director Department of Medical Oncology, University Hospital Essen; Spokesman for the German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Germany
14:20– 14:50	Precision therapy for Gynecological Cancers with focus on Endometrial (Uterine) Cancer: molecular subtypes and emerging treatment options Angela George : Clinical Director of Genomics and Consultant Medical Oncologist in Gynecology, Royal Marsden, London, UK
14:50 - 15:10	COFFEE BREAK
	Moderator: Tobias Schmidt Slørdahl , St. Olavs Hospital, Trondheim University Hospital
15:10 – 15:40	Advances in Multiple Myeloma Treatment Using Proteasome Inhibitors (The proteasome and proteasome inhibitors: from biology to clinical impact) Christoph Driessen , Professor, Head of Clinical Trial Unit, Department of Oncology and Hematology, Kantonsspital St Gallen, St Gallen, Switzerland
15:40– 16:10	Gut microbiome in the immunotherapy arena: from biomarker to therapeutics Bertrand Routy , Assistant Professor of Hemato-Oncology, Centre de recherche - Centre hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
16:10 – 16:15	Closing
From 16:15	On-site Networking Session (details tbd based on COVID-related restrictions in Jan)